Revenue ($USD): $27,400,000,000
R&D spend: $2,488,000,000.00
Employees: not available
Fiscal year end: 01/03/23
CEO: Joaquin Duato, CEO; Ashley McEvoy, EVP and J&J MedTech worldwide chair
In December, J&J boosted the profile of J&J MedTech inside the company throughits $16.6 billion acquisition of Abiomedand its Impella heart pump portfolio for treating coronary artery disease and heart failure.
Meanwhile, EVP and MedTech worldwide chair Ashley McEvoyjoined the ranks of J&J’s top-paid executivesandstarted a two-year term as chair of the trade group AdvaMed.
Biosense Webster, which has a new president, Jasmina Brooks, is another bright spot. It’slaunched an atrial fibrillation (AFib) mapping catheter called Optrellwith TrueRef technology. Biosense Webster is alsomoving forward with its investigational Thermocool SmartTouch SF dual energy catheterfor treating AFib. The system enables doctors performing an ablation to toggle between two types of energy: pulsed-field and radiofrequency. It appears to be Johnson & Johnson MedTech’s answer to Affera, which competitor Medtronic acquired for $1 billion last year.
As for the DePuy Synthes ortho device business, ithas a new major partnership with GE HealthCarein the spine surgery space.
On the flip side, the companyremains mostly quiet about its Ottava surgical robotics system, withsurgical robotics among the areaswhere J&J MedTechcut jobsearlier this year.–CN